Christopher Berger, MD

Education
07/2019 - Fellowship in Pulmonary and Critical Care Medicine, University of California San Francisco (UCSF)
06/2015 - Internal Medicine Residency, University of California San Francisco (UCSF)
MD, 05/2012 - Medicine, University of Pittsburgh
Masters in Tropical Medicine and International Health, 06/2007 - Tropical Medicine and International Health, Universitat Autònoma de Barcelona (UAB)
B.Phil, 12/2006 - International Health, University of Pittsburgh
Websites
Publications

  1. Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PPJ, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda. Open forum infectious diseases 2024. PMID: 39582503


  2. Crowder R, Kato-Maeda M, Schwem B, Dela Tonga A, Geocaniga-Gaviola DM, Lopez E, Valdez CL, Lim AR, Hunat N, Sedusta AG, Sacopon CA, Atienza GAM, Bulag E, Lim D, Bascuña J, Shah K, Basillio RP, Berger CA, Lopez MCDP, Sen S, Allender C, Folkerts M, Karaoz U, Brodie E, Mitarai S, Garfin AMC, Ama MC, Engelthaler DM, Cattamanchi A, Destura R. Impact of heteroresistance on treatment outcomes of people with drug-resistant TB. IJTLD open 2024. PMID: 39398438


  3. Musinguzi A, Kasidi JR, Kadota JL, Welishe F, Nakitende A, Akello L, Nakimuli J, Kunihira LT, Opira B, Baik Y, Patel D, Sammann A, Berger CA, Aschmann HE, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC, Katahoire AR. Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial. medRxiv : the preprint server for health sciences 2024. PMID: 39314926


  4. Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PP, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda. medRxiv : the preprint server for health sciences 2024. PMID: 39148841


  5. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS medicine 2024. PMID: 38377166


  6. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, Namale C, Kunihira Tinka L, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Patel D, Sammann A, Turyahabwe S, Dowdy DW, Katamba A, Cattamanchi A. Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. PLOS digital health 2023. PMID: 37390077


  7. Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023. PMID: 37231600


  8. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, Crowder R, Turyahabwe S, Katamba A, Cattamanchi A. Barriers and Facilitators to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in Uganda: Qualitative Study. Journal of medical Internet research 2023. PMID: 37252774


  9. Huddart S, Geocaniga-Gaviola DM, Crowder R, Lim AR, Lopez E, Valdez CL, Berger CA, Destura R, Kato-Maeda M, Cattamanchi A, Garfin AMC. Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines. PloS one 2022. PMID: 36346814


  10. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. 2015 Year Book of Pediatrics. Ed. Cabana MD. (Elsevier; Philadelphia, PA) 2021. PMID: 34914696


  11. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implementation science communications 2021. PMID: 34193311


  12. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Stavia T, Dowdy D, Katamba A. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS medicine 2021. PMID: 33956802


  13. Patel D, Berger CA, Kityamuwesi A, Ggita J, Kunihira Tinka L, Turimumahoro P, Feler J, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR formative research 2020. PMID: 33289494


  14. Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger CA, Tucker A, Patel D, Sammann A, Dowdy D, Stavia T, Cattamanchi A, Katamba A. Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ open 2020. PMID: 33247012


  15. Berger C, Patel D, Kityamuwesi A, Ggita J, Tinka LK, Turimumahoro P, Neville K, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. Opportunities to improve digital adherence technologies and TB care using human-centered design. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2020. PMID: 33126949


  16. Berger CA, Kityamuwesi A, Crowder R, Lamunu M, Kunihira Tinka L, Ggita J, Sanyu Nakate A, Namale C, Oyuku D, Chen K, Turyahabwe S, Cattamanchi A, Katamba A. Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2020. PMID: 33204851


  17. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation science : IS 2020. PMID: 32787925


  18. Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C. Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis. Annals of the American Thoracic Society 2020. PMID: 32464069


  19. Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, Berger CA, Kamya MR, Namusobya J, Semitala FC, Cattamanchi A, Dowdy DW. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2020. PMID: 32718409


  20. Vanderburg S, Alipanah N, Crowder R, Yoon C, Wang R, Thakur N, Slown K, Shete PB, Rofael M, Metcalfe JZ, Merrifield C, Marquez C, Malcolm K, Lipnick M, Jain V, Gomez A, Burns G, Brown LB, Berger C, Auyeung V, Cattamanchi A, Hendrickson CM. Management and Outcomes of Critically-Ill Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series. medRxiv : the preprint server for health sciences 2020. PMID: 32511538


  21. Chaka W, Berger C, Huo S, Robertson V, Tachiona C, Magwenzi M, Magombei T, Mpamhanga C, Katzenstein D, Metcalfe J. Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020. PMID: 32289564


  22. Cattamanchi A, Berger CA, Shete PB, Turyahabwe S, Joloba M, Moore DA, Davis LJ, Katamba A. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2019. PMID: 31879703